Navigation Links
Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing
Date:9/26/2007

Funds to Support Ongoing HCV Drug Discovery Projects

REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that it has obtained commitments from several institutional investors to purchase approximately 12.9 million shares of its common stock and warrants to purchase approximately 2.6 million shares of its common stock for gross proceeds of approximately $23.7 million. The investors have agreed to purchase the shares and warrants for $1.84 per unit (each unit consisting of one share and a warrant to purchase 0.20 shares of common stock). The exercise price of the warrants will be $2.08 per share. The warrants will be exercisable at any time prior to the fifth anniversary of the closing of the transaction. The closing of the offering is expected to take place on October 1, 2007, subject to satisfaction of customary closing conditions. Genelabs plans to use the proceeds from this financing to support its ongoing hepatitis C virus (HCV) drug discovery programs and for general corporate purposes. The proceeds will not be used to fund a new phase III clinical trial of Prestara. Deutsche Bank Securities Inc. acted as exclusive placement agent in the transaction.

A shelf registration statement relating to these securities (File No. 333-145497) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement when filed, can be obtained at the Securities and Exchange Commission's website, http://www.sec.gov, or from Genelabs.

Contact: James A. D. Smith

President and Chief Executive Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers Develop Technologies to Devour Food Pathogens
2. Researchers Study Safety of Assisted Reproductive Technologies
3. India to Propose Global Fund for Clean Energy Technologies
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... ... New patients who want to experience the benefits of dental implants ... by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is a respected ... each dental implant placement. The i-CAT CBCT system captures the shapes of oral structures ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of the ... Sudeep Roy, MD, was recently published in the American Journal of Cosmetic Surgery. “The ... Buckingham and Roy’s study on the use of Electro Lube during the facelift procedure. ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO ... Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle ... Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access to ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first name ... the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to products ... as ANSI, ISO and proven test methods used in the field of Vision ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017  A new survey from the ... Competitive Bidding Program (CBP) significantly reduced beneficiary choice and ... of choice forces beneficiaries to switch to unfamiliar or ... AADE,s survey is the latest in ... pointing out the inherent problems with the CBP. Last ...
(Date:3/27/2017)... /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or ... is pleased to announce it has received conditional approval ... TSX Venture Exchange.  Receiving the conditional ... significant achievements for Invictus-MD. Some of which include: ... Laboratories Inc. ("AB Labs"), a Licensed Producer under the ...
(Date:3/27/2017)... , March 27, 2017 ... as the NASDAQ Composite closed the trading session up ... and the S&P 500 was down 0.08%. US markets ... sectors finishing the day in green. Pre-market today, Stock-Callers.com ... Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), ...
Breaking Medicine Technology: